Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a note issued to investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 25.5 %

NASDAQ:BLPH opened at $0.01 on Thursday. Bellerophon Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.02. The company’s 50 day moving average is $0.03 and its 200-day moving average is $0.04. The firm has a market cap of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.